HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models (AACR 2023) - Mar 14, 2023 - Abstract #2660 / 28; Pres time: Apr 17, 2023; 01:30 PM - 05:00 PM; Location: Section 13; Poster Board #28; "Patritumab-Deruxtecan (U3-1402), a HER3-targeting ADC, showed clinical response in a subset of EGFR mutant and TKI resistant lung cancers in a Phase 1 study, albeit with toxicities including severe interstitial lung disease (ILD) and high grade cytopenias. In conclusion, HMBD-501 represents a next generation HER3 targeting ADC that has a potentially best-in-class efficacy and tolerability profile. Our findings strongly support the development of HMBD-501 as a promising candidate in the treatment of HER3 expressing solid tumors."
Preclinical • Colorectal Cancer • Genito-urinary Cancer • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • EGFR • FCGR2A • NRG1
|
|
Suhail Ahmed Kabeer Rasheed; Dipti Thakkar; Shalini Paliwal; Wen Jie Chin; Akshaya Bansal; Ben Ayers; Cheng Theng Ng; Brendon Hanson; Piers Ingram; Jerome Boyd-Kirkup
|